Crinetics Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2021-09-01

Reporting Person: Knight Jeff E. (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-01	Stock Option (right to buy)	$23.98	A	160000	Acquired	2031-08-30	Common Stock (160000)	Direct

Footnotes

F1: The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.